Multidrug resistance gene-1 polymorphisms and resistance to cyclosporine A in patients with steroid resistant ulcerative colitis

Inflammatory Bowel Diseases

Volumn 13, Issue 1, 2007, Pages 19-23

  Daniel, Fady ^a   Loriot, Marie Anne ^a   Seksik, Philippe ^b   Cosnes, Jacques ^b   Gornet, Jean Marc ^c   Lémann, Marc ^c   Fein, Francine ^d   Vernier Massouille, Gwenola ^e   De Vos, Martine ^f   Boureille, Arnaud ^g   Treton, Xavier ^h   Flourié, Bernard ⁱ   Roblin, Xavier ^j   Louis, Edouard ^k   Zerbib, Frank ^l   Beaune, Philippe ^a   Marteau, Philippe ^m  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b HÔPITAL SAINT ANTOINE   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^e LILLE UNIVERSITY HOSPITAL   (France)

^f Department of Gastroenterology   (Belgium)

^g HÔTEL DIEU   (France)

^h BEAUJON HOSPITAL   (France)

ⁱ HOSPICES CIVILS DE LYON   (France)

^j GRENOBLE UNIVERSITY HOSPITAL   (France)

^k UNIVERSITY OF LIÈGE   (Belgium)

^l HÔPITAL SAINT ANDRÉ   (France)

^m HÔPITAL LARIBOISIÈRE   (France)

more..

Author keywords

Cyclosporine; Multidrug resistance gene 1; Ulcerative colitis

Indexed keywords

CYCLOSPORIN A; MULTIDRUG RESISTANCE PROTEIN 1; NUCLEASE; STEROID;

ADULT; ALLELE; ARTICLE; BELGIUM; COLON RESECTION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG TREATMENT FAILURE; EXON; FEMALE; FRANCE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REMISSION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; ULCERATIVE COLITIS;

ADULT; COLITIS, ULCERATIVE; CYCLOSPORINE; DRUG RESISTANCE, MULTIPLE; FEMALE; GENE FREQUENCY; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; P-GLYCOPROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 33846157742     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20046     Document Type: Article

References (31)

1. Carter MJ, Lobo AJ, Travis SP, and IBD Section, British Society of Gastroenterology. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004;53(Suppl 5):V1-V16.
2. Marteau P, Seksik P, Beaugerie L, et al. Recommendations for clinical practice for the treatment of ulcerative colitis. Gastroenterol Clin Biol. 2004;28:955-960.
3. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994;330:1841-1845.
4. Arts J, D'Haens G, Zeegers M, et al. Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis. Inflamm Bowel Dis. 2004;10:73-78.
5. Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology. 2005;28:1805-1811.
6. Saeki T, Ueda K, Tanigawara Y, et al. Human P-glycoprotein transports cyclosporin A and FK 506. J Biol Chem. 1993;268:6077.
7. Schwab M, Eichelbaum M, Fromm MF. Genetic polymorphisms of the human MDR1 drug transporter. Annu Rev Pharmacol Toxicol. 2003;43:285-307.
8. Schwab M, Schaeffeler E, Marx C, et al. Association between the 3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. Gastroenterology. 2003;124:26-33.
9. Ho GT, Nimmo ER, Tenesa A, et al. Allelic variations of the multidrug resistance gene (MDR1) determine susceptibility and disease behaviour in ulcerative colitis. Gastroenterology. 2005;128:288-296.
10. McGovern D, Ahmad T, Van Heel D, et al. A genetic panel strongly predicts the need for colectomy in ulcerative colitis. Gastroenterology. 2004;26:A525.
11. Palmieri O, Latiano A, Valvano R, et al. Multidrug resistance 1 gene polymorphisms are not associated with inflammatory bowel disease and response to therapy in Italian patients. Aliment Pharmacol Ther. 2005;22:1129-1138.
12. Travis SP. Review article: the management of mild to severe acute ulcerative colitis. Aliment Pharmacol Ther. 2004;20(Suppl 4):88-92.
13. Anglicheau D, Verstuyft C, Laurent-Puig P, et al. Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J Am Soc Nephrol. 2003;14:1889-1896.
14. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA. 2000;97:3473-3478.
15. Bernal ML, Sinues B, Fanlo A, et al. Frequency distribution of C3435T mutation in exon 26 of the MDR1 gene in a Spanish population. Ther Drug Monit. 2003;25:107.
16. Farrell RJ, Murphy A, Long A, et al. High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy. Gastroenterology. 2000;118:279-288.
17. Langmann T, Moehle C, Mauerer R, et al. Loss of detoxification in inflammatory bowel disease: dysregulation of pregnane X receptor target genes. Gastroenterology. 2004;127:26-40.
18. Gazouli M, Zacharatos P, Gorgoulis V, et al. The C3435T MDR1 gene polymorphism is not associated with susceptibility for ulcerative colitis in Greek population. Gastroenterology. 2004;126:367-369.
19. Croucher PJ, Mascheretti S, Foelsch UR, et al. Lack of association between the C3435T MDR1 gene polymorphism and inflammatory bowel disease in two independent Northern European populations. Gastroenterology. 2003;125:1919-1920.
20. Hesselink DA, Van Schaik RH, Van der Heiden IP, et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther. 2003;74:245-254.
21. Yates CR, Zhang W, Song P, et al. The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients. J Clin Pharmacol. 2003;43:555-564.
22. Von Ahsen N, Richter M, Grupp C, et al. No influence of the MDR1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients. Clin Chem. 2001;47:1048-1052.
23. Mai I, Stormer E, Goldammer M, et al. MDR1 haplotypes do not affect the steady-state pharmacokinetics of cyclosporine in renal transplant patients. J Clin Pharmacol. 2003;43:1101-1107.
24. Hesselink DA, van Gelder T, van Schaik RH, et al. Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR1, CYP3A4, and CYP3A5 genes. Clin Pharmacol Ther. 2004;76:545-556.
25. Bonhomme-Faivre L, Devocelle A, Saliba F, et al. MDR1 C3435T polymorphism influences cyclosporine a dose requirement in liver-transplant recipients. Transplantation. 2004;78:21-25.
26. Brant SR, Panhuysen CI, Nicolae D, et al. MDR1 Ala893 polymorphism is associated with inflammatory bowel disease. Am J Hum Genet. 2003;73:1282-1292.
27. Potocnik U, Ferkolj I, Glavac D, et al. Polymorphisms in multidrug resistance 1 (MDR1) gene are associated with refractory Crohn disease and ulcerative colitis. Genes Immun. 2004;5:530-539.
28. Sambuelli A, Negreira S, Gil A, et al. Multidrug resistance Gene (MDR1) expression in intestinal mucosa of patients with refractory ulcerative colitis [Abstract]. Gastroenterology. 2005;28:A-156.
29. Fiedler T, Buening C, Reuter W, et al. Mdr1 genotypes determine early onset and severe course of disease in ulcerative colitis [Abstract T1026]. Gastroenterology. 2005.
30. Sambuelli A, Negreira S, Gil A, et al. Multidrug resistance gene (MDR1) expression in intestinal mucosa of patients with refractory ulcerative colitis [Abstract]. Gastroenterology. 2005;28:A-156.
31. Fiedler T, Buening C, Reuter W, et al. Mdr1 genotypes determine early onset and severe course of disease in ulcerative colitis. Gastroenterology. 2005;28:[Abstract T1026].